<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interferon alpha contains a sequence motif similar to the complement receptor type two (CR2/CD21) binding site on complement fragment C3d </plain></SENT>
<SENT sid="1" pm="."><plain>Antibodies against a <z:chebi fb="7" ids="16670">peptide</z:chebi> with the CR2 binding sequence on C3d react with a <z:chebi fb="7" ids="16670">peptide</z:chebi> carrying the IFN alpha CR2 binding motif (residues 92-99) and with recombinant IFN alpha </plain></SENT>
<SENT sid="2" pm="."><plain>The IFN alpha-derived <z:chebi fb="7" ids="16670">peptide</z:chebi>, as well as recombinant IFN alpha, inhibits C3bi/C3d interaction with CR2 on the Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> Raji </plain></SENT>
<SENT sid="3" pm="."><plain>The direct interaction of IFN alpha and CR2 is inhibited by polyclonal anti-IFN alpha, anti-CR2 and anti-C3d <z:chebi fb="7" ids="16670">peptide</z:chebi> antibodies as well as by C3bi/C3d, EBV coat protein gp350/220 and IFN but not by IFN gamma </plain></SENT>
<SENT sid="4" pm="."><plain>[125I]IFN alpha binding to Raji cells is inhibited by polyclonal anti-IFN alpha and anti-CR2 antibodies, by <z:chebi fb="7" ids="16670">peptides</z:chebi> with the CR2 binding motif and partially by C3bi/C3d </plain></SENT>
<SENT sid="5" pm="."><plain>Monoclonal anti-CR2 antibody HB5, but not OKB-7, blocks IFN alpha binding to Raji cells </plain></SENT>
<SENT sid="6" pm="."><plain>CR2 or CR2-like molecules may therefore be the major IFN alpha receptors on B lymphocytes </plain></SENT>
</text></document>